Defence Therapeutics (TSE:DTC) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Defence Therapeutics is exploring the use of its Accum technology to enhance the efficacy and prolong the half-life of GLP-1 agonists in treating obesity and related conditions such as type 2 diabetes. The company aims to address challenges like tolerability, injection frequency, and patient compliance, amidst a rapidly growing market for GLP-1 receptor agonists, projected to be worth over US$ 125 billion by 2033.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.